

IN THE CLAIMS:

Please add new claims 46 through 60, as set forth below. Please cancel claims 1 through 45 without prejudice or disclaimer. Applicants note that all claims now pending in the application are shown below for clarity, except claims 1 through 45, which are canceled herein.

Please add the following new claims:

Sub C1
46. A dosage form comprising:
a formulation comprising a therapeutic agent;
a first membrane in contact with said formulation, the first membrane being formulated such that the permeability of the first membrane is responsive to changes in osmotic pressure;
and
a second membrane in contact with said first membrane.

A2
47. The dosage form of claim 46, wherein said second membrane is a semipermeable membrane.

Sub C2
48. The dosage form of claim 46, wherein said first and second membrane form an internal compartment containing the formulation.

49. The dosage form of claim 46, wherein the second membrane is formulated to maintain the integrity of the dosage form as the dosage form delivers the therapeutic agent.

50. The dosage form of claim 46, wherein the permeability of the second membrane remains substantially constant during operation of the dosage form.

51. The dosage form of claim 46, wherein the integrity of the first membrane degrades during operation of the dosage form.

52. The dosage form of claim 46, wherein the first membrane comprises a hydrophilic substance and a hydrophobic substance.

Sub C3
53. The dosage form of claim 52, wherein the hydrophilicity of the hydrophilic substance ~~is~~ changes in response to changes in ~~osmotic~~ pressure.

54. The dosage form of claim 46, wherein the first membrane is formulated such that the permeability of the first membrane increases in response to a decrease in osmotic pressure.

55. The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane are formulated and configured to deliver the therapeutic agent in an extended, non-declining release profile.

12
56. The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 30 minutes to about 24 hours.

57. The dosage form of claim 55, wherein the extended, non-declining release profile comprises a period of about 4 hours to about 24 hours.

58. The dosage form of claim 46, wherein the formulation, the first membrane, and the second membrane, are formulated and configured to deliver the therapeutic agent in a zero-order release profile.

59. The dosage form of claim 46, further comprising an expandable layer.

Sub
C4
A2

60. A method of delivering a therapeutic agent to a subject, the method comprising:
administering a dosage form to the subject, the dosage form comprising a formulation including
the therapeutic agent, a first membrane that is in contact with said formulation and exhibits a
permeability responsive to changes in osmotic pressure, and a second membrane in contact with
said first membrane.

Please cancel claims 1 through 45 without prejudice or disclaimer.